Myopia Profile Sign in Sign in

Adding atropine for DIMS non-responders

Posted on November 21st 2026 by Kate Gifford In this article:

Some children continue to progress despite wearing Defocus Incorporated Multiple Segments (DIMS) spectacle lenses, a widely used myopia treatment. This research examined the effect of adding 0.025% atropine and explored differences in pupil constriction between fast and slow progressors. 

Paper title: Reduced myopia progression with low-dose atropine in DIMS non-responders and evidence of altered pupillary light reflex kinetics.

Authors: Domsa P(1,2), Törcsvári A(3), Baross V(1,4), Körtvélyes J(1,5), Széchey R(1,4), Csutak A(2), Bankó ÉM(6,7)

  1. Non Plus Ultra Vision Centre, Budapest, Hungary.
  2. Department of Ophthalmology, University of Pécs Medical School, Pécs, Hungary.
  3. Arcanum Development Ltd, Budapest, Hungary.
  4. Semmelweis University of Medicine, Budapest, Hungary.
  5. Heim Pál National Paediatric Institute, Budapest, Hungary.Non Plus Ultra Vision Centre, Budapest, Hungary. banko.eva@ttk.hu.
  6. HUN-REN Research Centre for Natural Sciences, Magyar tudósok krt. 2, Budapest, 1117, Hungary. banko.eva@ttk.hu.

Date: Jul 2026

References: Domsa P, Törcsvári A, Baross V, Körtvélyes J, Széchey R, Csutak A, Bankó ÉM. Reduced myopia progression with low-dose atropine in DIMS non-responders and evidence of altered pupillary light reflex kinetics. Sci Rep. 2026 Jul 13

[Link to open access paper]

Summary

Myopia control response varies between children, and continued progression can occur despite evidence-based treatment. Combining optical and pharmacological treatments may offer an option for these children, while identifying characteristics associated with continued progression could help inform their management.

This mixed-methods study included 72 children aged 6 to 17 years managed with DIMS spectacle lenses. In the longitudinal component, 20 children with continued progression received nightly 0.025% atropine for 12 months, with axial length and refractive progression compared with their previous DIMS-only period. A separate cross-sectional analysis compared dynamic pupillometry between 26 fast progressors and 34 slow or non-progressors. 

Key study outcomes were as follows: 

  • After 0.025% atropine was added, mean axial elongation decreased from 0.39 to 0.20 mm / year and refractive progression from -0.82 to -0.28 D/year compared with the preceding DIMS-only period. 
  • Five of 20 patients remained non-responsive to combination therapy, indicating variability in treatment response.
  • Fast DIMS progressors had slower maximum and average pupil constriction velocities compared with slow progressors. Dilation measures and pupil diameter did not differ between groups.
  • No major side effects were reported with 0.025% atropine during the 12-month treatment period.


What does this mean for my practice?

For children who continue to progress despite consistent DIMS spectacle wear, adding 0.025% atropine may offer an option for treatment escalation. In this small cohort, both axial elongation and refractive progression were lower during the 12 months of combination treatment than during the preceding DIMS-only period. However, without a concurrent control group, the extent to which this change can be attributed to atropine remains uncertain.

The pupillometry findings are exploratory at this stage. Slower pupil constriction was associated with faster progression during DIMS treatment, but the study did not establish whether pupillometry can predict future progression or treatment response. Further research is needed before these measurements can be used to guide treatment decisions.

What do we still need to learn?

The combination-therapy group was small and there was no DIMS-only or placebo-control comparison group. Larger, controlled studies are needed to confirm the effect of adding 0.025% atropine and determine whether the observed reduction in progression is sustained beyond one year.

The children in the study were classified according to their previous progression with DIMS, so this study was unable to establish whether pupil constriction measures can predict future progression or treatment response. Larger studies are also needed to clarify the mechanisms underlying altered pupil constriction and identify factors associated with poor response to combination treatment. 

Abstract

This study evaluated the efficacy of adding nightly 0.025% atropine to Defocus Incorporated Multiple Segments (DIMS) spectacle treatment in children with ongoing myopia progression and explored whether dynamic pupillometry could help identify such progression. In a mixed-method design, a longitudinal arm included 20 DIMS non-responders, defined by annual progression of ≥ 0.5 D spherical equivalent refraction or ≥ 0.2 mm axial elongation, who received adjunctive atropine and were followed for 12 months. In a separate cross-sectional arm, dynamic pupillometry was performed in 60 DIMS-treated children classified as fast or slow progressors based on prior-year progression. Combination therapy significantly reduced myopia progression, with mean axial elongation decreasing from 0.39 ± 0.18 to 0.20 ± 0.18 mm/year and mean refractive progression improving from - 0.82 ± 0.67 to - 0.28 ± 0.45 D/year. Transient axial shortening was observed in 20% of patients, while 25% remained unresponsive, predominantly those with high maternal myopia. Dynamic pupillometry revealed that fast progressors exhibited slower and prolonged pupil constriction compared with slow progressors, whereas dilation parameters and static pupil size did not differ. In conclusion, adjunctive low-dose atropine effectively reduced progression in most DIMS non-responders, and altered pupil constriction dynamics may reflect underlying physiological differences associated with treatment resistance.

[Link to abstract]

Back to all articles

Enormous thanks to our visionary sponsors

Myopia Profile’s growth into a world leading platform has been made possible through the support of our visionary sponsors, who share our mission to improve children’s vision care worldwide. Click on their logos to learn about how these companies are innovating and developing resources with us to support you in managing your patients with myopia.